1 reason to sell DexCom stock and 1 reason to buy | 21.12.24

Shares of medical device maker DexCom (NASDAQ: DXCM) are down 37% this year. The diabetes healthcare company disappointed investors with its second-quarter results, causing its stock price to drop massively overnight. While the issues DexCom has faced this year can be primarily categorized as “near-term headwinds” – including issues related to rebates – there are more serious issues for the company’s long-term prospects. On the other hand, DexCom has some interesting opportunities. this could allow it to offer market-beating returns to patient investors. Is the bullish scenario stronger than the bearish scenario? Let’s consider one argument against investing in DexCom and one in favor. DexCom develops continuous glucose monitoring (CGM) systems to help people with diabetes track their blood sugar levels. This technology improves patient health outcomes. This is why DexCom has been successful, at least so far. Increased adoption of CGM has led to revenue and profit growth: Continue readingMore articles on MotleyFool More articles on MotleyFool